What is the evidence for macrolide therapy in chronic rhinosinusitis?

Marina N. Cavada*, Jessica W. Grayson, Raymond Sacks

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    2 Citations (Scopus)


    Purpose of review: To assess the most recent evidence for macrolide therapy in chronic rhinosinusitis (CRS). Recent findings: Macrolides play a significant role in a select group of patients with CRS. Low-serum and tissue eosinophilia in patients who do not respond to corticosteroid therapy appeared to be an effective predictor of a CRS phenotype suitable for a trial of long-term macrolide therapy. Therapies using half a dose for longer than 12 weeks have noted good outcomes. Summary: The anti-inflammatory and immunomodulatory effects of macrolides have been demonstrated in several studies. Macrolides have shown an important role in patients who are nonresponsive to corticosteroid therapies, therefore patient selection is key. Previous inconsistencies in results may be due to poor patient selection.

    Original languageEnglish
    Pages (from-to)6-10
    Number of pages5
    JournalCurrent Opinion in Otolaryngology and Head and Neck Surgery
    Issue number1
    Publication statusPublished - 1 Feb 2020


    • chronic rhinosinusitis
    • macrolides
    • sinusitis


    Dive into the research topics of 'What is the evidence for macrolide therapy in chronic rhinosinusitis?'. Together they form a unique fingerprint.

    Cite this